Outcome of Cytogenetics in Patients with Newly Diagnosed Extramedullary Myeloma Undergoing Stem-Cell Transplantation

IF 9.090 (2017)International audienc

Current challenges in cell and gene therapy: a joint view from the European Committee of the International Society for Cell & Gene Therapy (ISCT) and the European Society for Blood and Marrow Transplantation (EBMT)

Cell and gene therapy poses evolving challenges. The current article summarizes the discussions held by European Regional Committee of the International Society for Cell & Gene Therapy and the European Society for Blood and Marrow Transplantation (EBMT) on the current challenges in this field, focusing on the European setting. This article emphasizes the imperative assessment of real-world cell and gene therapy activity, advocating for expanded registries beyond hematopoietic transplantation and chimeric antigen receptor–T-cell therapy. Accreditation's role in ensuring standardized procedures, as exemplified by JACIE (The Joint Accreditation Committee of ISCT-Europe and EBMT), is crucial for safety. Access to commercial products and reimbursement variations among countries underscore the need for uniform access to advanced therapy medical products (ATMPs). Academic product development and point-of-care manufacturing face barriers to patient access. Hospital Exemption's potential, demonstrated by some initial experiences, may increase patient accessibility in individual situations. Regulatory challenges, including the ongoing European ATMPs legislation review, necessitate standardized criteria for Hospital Exemption and mandatory reporting within registries. Efforts to combat unproven therapies and fraud involve collaboration between scientific societies, regulatory bodies and patient groups. Finally, is important to highlight the vital role of education and workforce development in meeting the escalating demand for specialized professionals in the ATMP field. Collaboration among scientific societies, academic institutions, industry, regulatory bodies and patient groups is crucial for overcoming all these challenges to increase gene and cell therapy activity in Europe

Greenhouse gas reductions in Germany and the UK-coincidence or policy induced? An analysis for international climate policy

This brochure gives an overview of the underlying factors for greenhouse gas emission trends in Germany and the UK in the 1990s. The main focus of the brochure was to assess, to which extend the observed reductions of the specified basket of six greenhouse gases are the result of special circumstances, i.e. the reunification of Germany and the liberalisation of the energy markets in the UK, and to which extend these emissions reductions are the result of specific policy measures. For both of the country case studies it can be concluded that emission reductions arising from special circumstances account for 40-50% of the reductions for all Kyoto gases, and for almost 60% for energy-related CO_2 emissions. However, environmental policies in both countries also had a major impact on the reduction of greenhouse gases. Thus, the observed reductions are a mix of both, coincidence and hard work. Nevertheless, both countries, and perhaps the UK even more than Germany, might miss their national targets unless additional policies are implemented in the near future. (orig.)Available from TIB Hannover: RN 8908(2000,193) / FIZ - Fachinformationszzentrum Karlsruhe / TIB - Technische InformationsbibliothekSIGLEBundesministerium fuer Umwelt, Naturschutz und Reaktorsicherheit, Bonn (Germany)DEGerman